Open-Label Safety and Pharmacokinetic Study of Single (TDF), Dual (TDF-FTC), and Triple ARV IVR (TDF-FTC-MVC) in Healthy Women
Phase of Trial: Phase 0
Latest Information Update: 07 Feb 2017
At a glance
- Drugs Emtricitabine/maraviroc/tenofovir-disoproxil-fumarate (Primary) ; Emtricitabine/tenofovir disoproxil maleate (Primary) ; Tenofovir dipivoxil fumarate (Primary)
- Indications HIV infections
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors Auritec Pharmaceuticals
- 30 Jan 2017 Status changed from recruiting to completed.
- 04 Mar 2016 Planned End Date changed from 1 Jul 2016 to 1 Sep 2016 as reported by ClinicalTrials.gov.
- 04 Mar 2016 Planned primary completion date changed from 1 Mar 2016 to 1 Jun 2016 as reported by ClinicalTrials.gov.